Anti-citrullinated protein antibody
| Anti-citrullinated protein antibody |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Anti-citrullinated protein antibodies (ACPA) or anti-cyclic citrullinated protein antibodies (anti-CCP) are autoantibodies (antibodies against human tissues) frequently detected in rheumatoid arthritis. The main epitope for these antibodies is filaggrin, and there is cross-reactivity between ACPA and anti-keratin and anti-perinuclear factor.[1] In a comparative study, various detection kits had a sensitivity between 69.6% and 77.5% and a specificity between 87.8% and 96.4%.[2] Given that ACPA is more specific than rheumatoid factor, it is used to distinguish various causes of arthritis.[3]
References
- ↑ Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (January 1998). "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies". J. Clin. Invest. 101 (1): 273–81. doi:10.1172/JCI1316. PMID 9421490. Full text at PMC: 508564
- ↑ Coenen D, Verschueren P, Westhovens R, Bossuyt X (March 2007). "Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis". Clin. Chem. 53 (3): 498–504. doi:10.1373/clinchem.2006.078063. PMID 17259232.
- ↑ Avouac J, Gossec L, Dougados M (July 2006). "Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review". Ann. Rheum. Dis. 65 (7): 845–51. doi:10.1136/ard.2006.051391. PMID 16606649.
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
